• Ascletis Pharma submitted an investigational new drug application to the FDA for ASC39, an oral selective amylin receptor agonist for obesity.
• A Phase I trial is expected to begin in the fourth quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261026-12382441), on October 26, 2026, and is solely responsible for the information contained therein.